Sanofi Stock Nasdaq

Equities

SNY

US80105N1054

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-05-24 pm EDT 5-day change 1st Jan Change
48.54 USD -0.94% Intraday chart for Sanofi -0.27% -2.39%
Sales 2024 * 46.3B 50.21B Sales 2025 * 49.84B 54.06B Capitalization 112B 121B
Net income 2024 * 7.08B 7.68B Net income 2025 * 8.7B 9.44B EV / Sales 2024 * 2.56 x
Net Debt 2024 * 6.68B 7.25B Net Debt 2025 * 2.28B 2.47B EV / Sales 2025 * 2.29 x
P/E ratio 2024 *
16 x
P/E ratio 2025 *
12.9 x
Employees 86,088
Yield 2024 *
4.32%
Yield 2025 *
4.55%
Free-Float 87.13%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.94%
1 week-0.27%
Current month-1.40%
1 month-1.66%
3 months-0.47%
6 months+2.88%
Current year-2.39%
More quotes
1 week
48.35
Extreme 48.3451
50.59
1 month
48.10
Extreme 48.1
50.59
Current year
45.22
Extreme 45.22
52.79
1 year
42.63
Extreme 42.63
55.72
3 years
36.91
Extreme 36.91
58.10
5 years
36.91
Extreme 36.91
58.10
10 years
36.81
Extreme 36.8101
58.10
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 19-08-31
Chief Operating Officer 40 21-12-31
Chief Tech/Sci/R&D Officer 51 -
Members of the board TitleAgeSince
Director/Board Member 70 14-04-30
Director/Board Member 64 20-05-21
Chairman 60 22-09-01
More insiders
Name Weight AuM 1st Jan change Investor Rating
1.56% 9 M€ -4.31% -
More ETFs positioned on Sanofi
Date Price Change Volume
24-05-24 48.54 -0.94% 1,423,816
24-05-23 49 -2.70% 2,781,532
24-05-22 50.36 +2.88% 2,119,999
24-05-21 48.95 +1.09% 725,653
24-05-20 48.42 -0.51% 1,273,831

Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT

More quotes
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
89.52 EUR
Average target price
108.2 EUR
Spread / Average Target
+20.86%
Consensus